Goldman Sachs Group Inc Crispr Therapeutics Ag Transaction History

Goldman Sachs Group Inc

$580 Billion
Q2 2024

A detailed history of Goldman Sachs Group Inc transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Goldman Sachs Group Inc holds 265,347 shares of CRSP stock, worth $13.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

265,347

Previous 132,697 99.96%

Holding current value

$13.2 Million

Previous $9.04 Million 58.46%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$51.17 - $68.18 $6.79 Million - $9.04 Million	132,650 Added 99.96%	265,347 $14.3 Million
Q1 2024 May 15, 2024	SELL	$60.67 - $89.12 $3.33 Million - $4.89 Million	-54,923 Reduced 29.27%	132,697 $9.04 Million
Q4 2023 Feb 13, 2024	BUY	$38.62 - $72.18 $2.46 Million - $4.59 Million	63,575 Added 51.25%	187,620 $11.7 Million
Q3 2023 May 14, 2024	SELL	$45.39 - $59.0 $2.89 Million - $3.75 Million	-63,575 Reduced 33.88%	124,045 $5.63 Million
Q3 2023 Nov 14, 2023	SELL	$45.39 - $59.0 $610,041 - $792,960	-13,440 Reduced 9.78%	124,045 $5.63 Million
Q2 2023 May 14, 2024	SELL	$43.47 - $67.77 $4.35 Million - $6.77 Million	-99,969 Reduced 42.1%	137,485 $7.72 Million
Q2 2023 Aug 14, 2023	SELL	$43.47 - $67.77 $4.35 Million - $6.77 Million	-99,969 Reduced 42.1%	137,485 $7.72 Million
Q1 2023 May 14, 2024	SELL	$41.0 - $56.12 $10.7 Million - $14.6 Million	-259,779 Reduced 52.24%	237,454 $10.7 Million
Q1 2023 May 11, 2023	SELL	$41.0 - $56.12 $10.7 Million - $14.6 Million	-259,779 Reduced 52.24%	237,454 $10.7 Million
Q4 2022 May 14, 2024	SELL	$39.19 - $65.67 $9.75 Million - $16.3 Million	-248,673 Reduced 33.34%	497,233 $20.2 Million
Q4 2022 Feb 13, 2023	SELL	$39.19 - $65.67 $9.75 Million - $16.3 Million	-248,673 Reduced 33.34%	497,233 $20.2 Million
Q3 2022 May 14, 2024	BUY	$61.1 - $83.78 $15.3 Million - $21 Million	250,700 Added 50.63%	745,906 $48.7 Million
Q3 2022 Nov 10, 2022	BUY	$61.1 - $83.78 $15.3 Million - $21 Million	250,700 Added 50.63%	745,906 $48.7 Million
Q2 2022 May 14, 2024	BUY	$43.23 - $73.83 $13.3 Million - $22.7 Million	307,586 Added 163.94%	495,206 $30.1 Million
Q2 2022 Aug 15, 2022	BUY	$43.23 - $73.83 $16.4 Million - $28 Million	378,609 Added 324.72%	495,206 $30.1 Million
Q1 2022 May 16, 2022	SELL	$53.19 - $79.24 $2 Million - $2.98 Million	-37,589 Reduced 24.38%	116,597 $7.32 Million
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $12.2 Million - $19.4 Million	-173,896 Reduced 53.0%	154,186 $11.7 Million
Q3 2021 Nov 10, 2021	BUY	$110.2 - $156.64 $36.2 Million - $51.4 Million	328,082 New	328,082 $36.7 Million

Others Institutions Holding CRSP

# of Institutions

523

Shares Held

58M

Call Options Held

1.73M

Put Options Held

1.84M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.87B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Crispr Therapeutics Ag Transaction History